CURRICULUM VITAE

**Robert G. BOTA, MD, MSG, DFAPA**

PERSONAL DATA

Current address: 3151 Airway Ave, Bld R

Costa Mesa, CA 92626

949-228-5377

Bota4TMS@gmail.com

PERSONAL STATEMENT

The focus of my clinical activities and of my patient-oriented research has always been on understanding the interplay between psychiatric illnesses and medical conditions and on developing innovative ways of addressing the whole spectrum of psychosomatic needs in patients with complex presentations. As a psychiatrist, I have a broad background in diagnosing and treating mental illness. Before my residency, I designed and conducted neuro-imaging research focused on correlations between structural brain changes and depression. Since the beginning of my residency in psychiatry, I have become interested in the interplay between medicine and psychiatry, especially the diagnostic and treatment of psychiatric conditions in medically ill patients – which present unique challenges due to their multiple comorbidities and the high risk of drug interactions.

From 2005 to 2014 I developed a very successful practice working for the State and then for Kaiser Permanente where I also served as the Chair of Research for Riverside area.

From 2014-2019, I served as the director of medical psychiatry unit and the director of TMS clinic at University of California, Irvine. I am still very involved in teaching residents, fellow as well as medical students and in patient-based research and treatment approaches for the most complicated patients.

In my role as a faculty at UC Riverside I am involved in several clinical, teaching and research activities:

Teaching: I teach the interventional Psychiatry course and occasionally give GR presentations

Research: Since 2020 I am the principal investigator at CI Trials (former affiliated with UC Riverside) where I conduct over 20 clinical trials (stage 2 and 3) addressing many psychiatric conditions, such as AD, schizophrenia, MDD, PTSD and others.

Currently, my clinical activities are focused on treating patients with complex medical, substance use and mental illness comorbidities. I offer second opinion clinics, transcranial magnetic stimulation treatment and dementia diagnosis using quantitative EEG event-related potentials.

EDUCATION, TRAINING AND EMPLOYMENT

June 2021- now Clinical Professor of Psychiatry, step 3 (p) and Human Behavior UC Riverside

December 2019-now Researcher- Principal Investigator at CITrials

November 2019-now Medical Director BrainHealth Solutions Inc.

October 2018-November 2019 Clinical Professor of Psychiatry and Human Behavior UC Irvine (Step 1 in 2018).

October 2014-June 2018 Associate Clinical Professor of Psychiatry and Human Behavior UC Irvine (Step 3 in 2015).

October 2008-September 2014 Staff psychiatrist, Kaiser Permanente, Riverside, CA

October 2005-October 2008 Staff Psychiatrist Middle Flint BHC and Sumter Regional Hospital in Americus, GA

August 2001- August 2005 Psychiatry Resident, Department of Psychiatry, Chief Resident for Psychiatry (2004–2005), University of Missouri at Kansas City

August 1999- June 2001 Master in Social Gerontology, University of Southern California, Andrus Gerontology Center

September 1997 M.D. Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

LICENSE AND CERTIFICATION

2009 Diplomat of the American Board of Psychiatry and Neurology

2008 License to practice medicine; California

ACADEMIC POSITIONS

May 2018-now Clinical Professor of Psychiatry and Human Behavior UC Irvine

2016-Present Distinguished Fellow of American Psychiatric Association

2012-2016 Fellow of American Psychiatric Association

2005-2016 Assistant Professor, Department of Psychiatry, School of Medicine, University of Missouri at Kansas City

PROFESSIONAL EXPERIENCE

2020-now President Orange County Psychiatric Society

2018-2020 President Elect Orange County Psychiatric Society

2018-2020 Nominating Committee Representative to California Psychiatric Association

2014-2019 Psychiatry rotation Director for chronic pain fellowship

2014-2019 Ethics Committee Orange County Psychiatric Society

2014-2019 Ethics Committee UC Irvine

2014-2018 Governmental Affairs Committee Orange County Psychiatric Society

2014-2018 Public Affairs Committee Orange County Psychiatric Society

2014-2014 Innovation Committee Member, Kaiser Permanente

2014-2014 Professional Education Committee Member, Kaiser Permanente

2011-2014 Research Chair, Kaiser Permanente, Inland Empire Region

2008-2014 Staff psychiatrist, Kaiser Permanente, Riverside, CA

2007-2008 Co-medical Director Geriatric Psychiatry Unit (12 beds), Byromville, GA

2007-2008 Medical Director Pinehill Nursing Home (101 beds), Byromville, GA

2006-2007 Interim Medical Director at Middle Flint BHC and Psychiatry Department, Sumter Regional Hospital in Americus, GA

2005-2008 Staff Psychiatrist Middle Flint BHC and Sumter Regional Hospital in Americus, GA

2005-now University of Missouri at Kansas City, Assistant Professor Department of Psychiatry,

2000-2001 University of California, Los Angeles, Staff Research Associate, Department of Psychiatry

2000-2001 University of Southern California, Research Assistant, Psycho-Gerontology department

1999-2000 University of Southern California, Teaching Assistant, Advanced Biochemistry

AREAS OF RESEARCH EXPERTISE

I. Neuromodulation

II. Schizophrenia Prodrome

III. Cognitive Changes and Insight

IV. Interrelations between Psychiatric Illnesses and Medical Conditions

V. Geriatric psychiatry

HONORS

1. Distinguished Fellow of American Psychiatric Association (2016)
2. Secretary for Orange County Psychiatric Association (2016)
3. Missouri Delegate at American Medical Association (2004-2005)
4. Edward E. Baumhardt Psychiatry Scholarship Award: Best Submitted Paper by a Senior Psychiatry Resident: "Implications of boarding home placement in patients with schizophrenia " 2005
5. Chief Resident for Psychiatry Program at UMKC (2004-2005).
6. House Staff Council representative of psychiatry program to UMKC GME committee (2004-05).
7. Resident representative for Education and Policy Committee at WMMHC (2003-2004).
8. Outstanding Teaching Assistant award, Department of Biology, USC (April 2000).
9. University Merit Fellowship 1992-1994 at University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania

PROFESSIONAL MEMBERSHIPS

Member in Clinical TMS Society

Member in Southern Medical Association Speaker’s Bureau

Member in American Association for Advancement in Science

Member in Romanian Medical Association (Asociatia Medicala Romana)

Member in Schizophrenia International Research Society

Member in American Psychiatric Association

Member in Southern Medical Association

EDITORIAL SERVICE

**EDITOR IN CHIEF**

2013 to now Mental Illness Journal- Pub Med indexed in 2015

EDITORIAL BOARD

2016 to now JSM Schizophrenia

2009 to 2013 Mental Illness Journal

2009 to now Rehabilitation Process and Outcome

2009 to now International Journal of Pain

2009 to now Journal of Clinical Medicine and Research

REVIEWER SERVICE

2011 to now Permanente Journal

2010 to now Educational Research

2009 to now Clinical Schizophrenia & Related Psychosis

2009 to now Mental Illness Journal

2007 to now British Medical Journal (BMJ)

2007 to now American Journal of Psychiatry

2006 to now Journal of Clinical Psychiatry

2005 to now Schizophrenia Research

2005 to now Central Nervous System (CNS) Spectrum

2005 to now British Psychiatric Journal (BPJ)

2003 to now Southern Medical Journal (SMJ)

SOURCES OF RESEARCH SUPPORT

*Ongoing Clinical Research*

*Research Experience*

Protocol TV46000-CNS-30072: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients with Schizophrenia

A Phase 3b Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects with Schizophrenia Treated Prospectively for 6-months with Abilify MyCite

A Study to Evaluate the Safety and Efficacy of NYX-783 in Subjects with Post-Traumatic Stress Disorder.

Principal investigator. A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 years of age) with Schizophrenia.

Co-Investigator. NIH 2015-2018 Mitochondrial Dysfunction in psychiatric episodes

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of ESN364 in Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause

Protocol 18-AVP-786-207: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Assess the Efficacy, Safety, and Tolerability of AVP- 786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of negative symptoms of schizophrenia

Phase 1, Multicenter, Open-Label, Dose-Escalation, Combination Study of Marizomib And Bevacizumab in Bevacizumab-Naive Subjects with WHO Grade IV Malignant Glioma (Triphase Research and Development I Corp.), (NPI-0052)

A Phase 2, Randomized, Double-Blind, Placebo Controlled Study To Assess The Effects Of Ro6889450 In Patients With Schizophrenia Or Schizoaffective Disorder And Negative Symptoms

Study of Marizomib With Temozolomide and Radiotherapy in Patients with Newly Diagnosed Brain Cancer

Protocol 2014-001-00: A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia (VISTA). Stanly Medical Research Institute

Identification of functional MRI and neuropsychiatric changes after marizomib treatment in patients enrolled in the UCI 14-58 study (single agent marizomib cohort), (Triphase Research and Development I Corporation)

Pilot study of mirtazapine for the dual treatment of depression and temozolomide-induced nausea and vomiting (CINV) in newly diagnosed glioma patients (Track 2), CFCCC- Pilot Project Award Co-PI

UC Reliance 793 - Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease- Protocol H8A-MC-LZAZ/ADC-040-A4

A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer’s Disease (US202).

A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder.

A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401in Subjects with Early Alzheimer Disease.

Alzheimer Disease Neuroimaging Initiative 2 (ADNI2) Protocol: ADC-039 Amendment 3 dated October 17, 2014 & Investigator Brochure AV45 (Florbetapir F 18) version 10 dated June 30, 2014.

A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease.

HS# 2016-3320, WIRB Reliance #20: A Randomized, Double-blind, Placebo-controlled, Multi-center Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder.

An Exploratory, Multicenter, Randomized, Double-blind, fMRI Study of Fixed-dose Brexpiprazole (OPC-34712) (2 and 4 mg/day tablets) in Adults with Schizophrenia with Impulsivity.

Randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with donepezil; study 2. Study # 14862A

A Trial to Evaluate the Safety, Eﬃcacy, and Tolerability of Brexpiprazole in Treating Agitation Associated with Dementia of the Alzheimer's Type

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects with Agitation Associated with Dementia of the Alzheimer's Type

Longitudinal Cohort Study of Resource use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease in the United States

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Eﬃcacy, and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's Disease

A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated with Valbenazine

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Eﬃcacy, Safety, and Tolerability of Risperidone Extended- Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult Patients With Schizophrenia

A Double-Blind, Placebo-Controlled Study of Cariprazine as an Adjunct to Antidepressant in the Treatment of Patients with Major Depressive Disorder who have had an Inadequate Response to Antidepressants

An Open-Label, Long Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated with Valbenazine

A Phase 4, Double Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects with Schizophrenia Treated Prospectively for 6-months with Abilify MyCite®

A Randomized, Double-Blind, Placebo Controlled Study of COR388 HCl in Subjects with Alzheimer’s Disease

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to-Moderate Alzheimer’s Disease

A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia (VISTA). Stanly Medical Research Institute

A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multi Center Study to Assess the Efficacy and Safety ofITI-007 Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder

 A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multi Center Study to Assess the Efficacy and Safety ofITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients with Dementia, Including Alzheimer’s Disease

An Open-Label, Multi-Center Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients with Military-Related PTSD Brexpiprazole

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-217 in the Treatment of Adult Female Subjects with Severe Postpartum Depression IND #: 132,131

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients with Major Depressive Disorder

An Open-Label, Long-Term Safety Study of Rapastinel as Adjunctive Therapy in Patients with Major Depressive Disorder

A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease.

An Open-Label Study to Evaluate the Efficacy and Tolerability of Ecopipam in Adults with Childhood Onset Fluency Disorder (Stuttering)

A Short-term, Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality

A Study to Evaluate the Safety and Efficacy NYX-783 in Subjects with Post-Traumatic Stress Disorder

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of negative symptoms of schizophrenia

A Randomized, Double-blind, Placebo-controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Stage Alzheimer’s Disease

A Randomized, Placebocontrolled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects with Tourette’s Disorder

A Randomized, Placebo controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects with Tourette’s Disorder

A double-Blind, Placebo-Controlled, Randomized withdrawal, Multicenter Clinical trial evaluating The Efficacy, Safety, And Tolerability of Cariprazineina dose-Reduction Paradigm In The prevention Of Relapse In Bipolar I Disorder Patients whose current episode Is Manic Or Depressive, With Or without mixed features.

A Double-Blind, Placebo-Controlled, Randomized withdrawal, Multicenter Clinical trial evaluating The Efficacy, Safety, And tolerability of Cariprazineina dose-Reduction Paradigm in the prevention Of Relapse In Patients With Schizophrenia

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of SAGE-217 with a Fixed, Repeated Treatment Regimen on Relapse Prevention in Adults with Major Depressive Disorder

A Phase 2, Randomized, Double-Blind, Placebo Controlled Study To Assess The Effects Of Ro6889450 In Patients With Schizophrenia Or Schizoaffective Disorder And Negative Symptoms

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD Taken Daily at Bedtime

A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance)Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects withTourette’sDisorder

Aripiprazole Partial Agonism at 5-HT2c: a Comparison of Weight Gain Associated with Adjunctive Aripiprazole to Antidepressants with High versus Low Serotonergic

Activities. Investigator-Initiated. Principal Investigator, Robert Bota.

Mindfulness- retrospective study. Investigator-Initiated. Principal Investigator: Robert Bota, Kaiser Research Foundation.

Insight dynamics in the Schizophrenia prodrome and the "tripartite model of the mind" an alternate explanation of cognitive dysmetria. University of Missouri at Kansas City, PI: Robert Bota.

Early Identification of Schizophrenia Prodrome. University of Missouri at Kansas City, Robert Bota.

A double blinded, randomized, placebo-controlled study of paroxetine and interpersonal therapy versus single agent paroxetine in patients with major depressive disorder.

11C Raclopride PET in smoking and non-smoking subjects. University of California, Los Angeles.

Emotional modulation in response to disturbing images in college students. University of Southern California.

A Randomized, Double-Blind, Placebo Controlled Study of COR388 HCl in Subjects with Alzheimer's Disease

A Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam in childhood onset of verbal disfluency

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 in Patients with Schizophrenia or schizoaffective disorder and Negative Symptoms

331-201-00072: A Phase 3, Multicenter, Randomized, Double-blind Trial of Fixed-Dose Brexpiprazole as Combination Therapy with Sertraline in the Treatment of Adults with Post-traumatic Stress-Disorder

KAR-011: An Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects with DSM-5 Schizophrenia

BP40283: phase 2, randomized, double-blind, placebo-controlled study to assess the effects of ro6889450 in patients with schizophrenia or schizoaffective disorder and negative symptoms

Precision 8200: a multiple visit, longitudinal collection, and banking of DNA/RNA/serum/ plasma/CSF/urine in normal donors

F. Hoffman-La Roche ltd - bp41743, a phase ii, multi-center, randomized, double-blind, parallel group, placebo controlled trial of the efficacy and the safety of ro6889450 (ralmitaront) vs. placebo in patients with an acute exacerbation of schizophrenia or Schizoaffective-Disorder (Pro00041537)

T3D Therapeutics, Inc. / “A Randomized, Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to Moderate Alzheimer’s Disease

Sample Registry Serial Alzheimer’s disease and MCI Prospective Longitudinal Evaluation Longitudinal cognition follow-up and serial DNA/RNA/SERUM/ PLASMA/CSF/URINE/SALIVA banking in donors with Mild Cognitive Impairment or Mild to Moderate Alzheimer’s disease

Protocol Number: 20-AVP-786-307 A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type

AXS-05-AD-302: A Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects with Dementia of the Alzheimer’s Type

An Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects with Major Depressive Disorder

A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 Versus Placebo in Subjects With Major Depressive Disorder

A Two-Part Study of CLE-100 as an Adjunct Therapy in Subjects With Major Depressive Disorder

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 Monotherapy for Major Depressive Disorder (The RELIANCE-III Study)

Phase 1, Multicenter, Open-Label, Dose-Escalation, Combination Study Of Marizomib And Bevacizumab In Bevacizumab-Naive Subjects With WHO Grade IV Malignant Glioma (Triphase Research and Development I Corp.), (NPI-0052): 2015-now

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer, 2016- Present

Identification of functional MRI and neuropsychiatric changes after marizomib treatment in patients enrolled in the UCI 14-58 study (single agent marizomib cohort), (Triphase Research and Development I Corporation), 2017-Present

Pilot study of mirtazapine for the dual treatment of depression and temozolomide-induced nausea and vomiting (CINV) in newly-diagnosed glioma patients (Track 2), CFCCC- Pilot Project Award Co-PI, 2018

*Past Clinical Research*

Co-Investigator. NIH 2015-2018Mitochondrial Dysfunction in psychiatric episodes: PI: VP Marquis, (2016- 2019)

Co-Investigator. UC Reliance 793 - Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease- Protocol H8A-MC-LZAZ/ADC-040-A4, PI: Steven Potkin, (2014- 2017)

Co-Investigator. A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer’s Disease (US202). PI: Steven Potkin, (2014- 2017)

Co-Investigator. A Phase 2, Efficacy, Safety, and Tolerability Study of **ALKS 3831** in Schizophrenia with Alcohol Use Disorder. PI: Steven Potkin, (2015- 2017)

Co-Investigator. A Placebo-controlled, Double-blind, Parallel-group, **Bayesian** Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401in Subjects With Early Alzheimer Disease. PI: Steven Potkin, (2014- 2017)

Co-Investigator. Alzheimer Disease Neuroimaging Innitiative 2 **(ADNI2)** Protocol: ADC-039 Amendment 3 dated October 17, 2014 & Investigator Brochure AV45 (Florbetapir F 18) version 10 dated June 30, 2014. PI: Steven Potkin, (2014- 2017)

Co-Investigator. "A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease" PI: Steven Potkin, (2014- 2017)

Co-Investigator. HS# 2016-3320, "WIRB Reliance #20: A Randomized, Double-blind, Placebo-controlled, Multi-center Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder" PI: Steven Potkin, (2014- 2017)

Co-Investigator. An Exploratory, Multicenter, Randomized, Double-blind, fMRI Study of Fixed-dose **Brexpiprazole** (OPC-34712) (2 and 4 mg/day tablets) in Adults with Schizophrenia with Impulsivity. PI: Steven Potkin, (2014- 2016)

Co-Investigator. Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with donepezil; study 2. Study # 14862A. PI: Steven Potkin, (2014- 2017)

Aripiprazole Partial Agonism at 5-HT2c: a Comparison of Weight Gain Associated with Adjunctive Aripiprazole to Antidepressants with High versus Low Serotonergic Activities. Investigator-Initiated. Principal Investigator: Robert Bota, Kaiser Research Foundation, 40,000$ (2013-14)

Mindfulness- retrospective study. Investigator-Initiated. **Principal Investigator: Robert Bota,** Kaiser Research Foundation, 38,000$ (2013-14)

Insight dynamics in the Schizophrenia prodrome and the "tripartite model of the mind" an alternate explanation of cognitive dysmetria. University of Missouri at Kansas City, PI: Robert Bota (2006-2012).

Early Identification of Schizophrenia Prodrome. University of Missouri at Kansas City, PI: Robert Bota (2002-2006).

Co-Investigator. A double blinded, randomized, placebo-controlled study of paroxetine and interpersonal therapy versus single agent paroxetine in patients with major depressive disorder. University of California, Los Angeles. PI: Arthur Brody (2000-2001).

Co-Investigator. 11C Raclopride PET in smoking and non-smoking subjects. University of California, Los Angeles. PI: Arthur Brody (2000-2001).

Co-Investigator. Emotional modulation in response to disturbing images in college students. University of Southern California, PI: Bob Knight (1999-2001).

JOURNAL ARTICLES AND BOOK CHAPTERS– PEER REVIEWED

1. Knox D, PhD, **Bota RG, MD** “Transcranial magnetic stimulation-associated mania with psychosis: A case report” Ment Health Clin, 2021 Nov 8;11(6):373-375
2. Jacobson Werdet, J, PhD, Thanh GT, PhD, Paul, D, MD, **Bota, RG, MD**, [Interactions between antidepressants, sleep aids and selected breast cancer therapy](https://www.researchgate.net/publication/333713451_Interactions_between_antidepressants_sleep_aids_and_selected_breast_cancer_therapy?_sg=qJMAJd0s6jBjWMrQCjBE1O3E6uULGbbCi5saoVRc17kbnF2_fwvVnWEfIcAfMCYckSpN62nR37YGnU6nYxEkkceYS8xFOlmyqm_uqrow.ryAH2s7g3b2Z-LkGJnwCuDq7ITfr26pou1szngniDC7Jp1g4Qnk12O-LSGxj6XFDWIRqgmSv9U_84iimnzEeTg), Mental Illness Journal, June 2019
3. Novac, A, MD, Tuttle, MC, MD, Bota, RG, MD, Blinder, BJ, “Identity Narrative as an Unconscious Scafold for Human Autobiography” New Studies and research in multidisciplinary fields, March 2019
4. Sampathi, BR, BS, Sofine, A, MD, Alvarez, J, MD, **Bota, RB, MD**, “Capgras syndrome in substance-induced psychosis”, Mental Illness Journal, 10(2), DOI: 10.4081/mi.2018.7807, 2018
5. Keator, DB, MD, **Bota, RG, MD**, Small, SL, MD, Bota, DA, MD, “Longitudinal Resting state functional connectivityconfirms marizomib crosses the blood brain barrier and correlates with hallucination severity in reccurent GBM patieints”, Neurology-Oncology, 20 (suppl-6), VI186, DOI:

10.1093/neuonc/noy148.772, 2018

1. Lai, L, MD, “Emergency department wait times for geriatric psychiatric patients” Primary Care Companion CNS Disorders, 2018
2. Fedoce, AG, PhD, **Bota RG**, MD, Bonet-Costa, V, PhD, Davies, JA, PhD, “The role of Oxidative Stress in Anxiety disorder: Cause or Consequence”, Free Radical Research, 2018
3. Couse, M, Wojtanowicz, T, MD, Comeau, S, MD, **Bota, RG, MD**, “Peduncular hallucinosis associated with a pontine cavernoma”, Mental Illness Journal, 1. doi: 10.4081/mi.2018.7586, 2018
4. Torosyan, N, Spencer, D, Penev, S, MD, **Bota, RG, MD,** “Psychogenic polydipsia in a woman with anorexia nervosa: case report and recommendations”, Primary Care Companion CNS Disorders, 8;20(1), 2018
5. **Bota, RG, MD**, Bota, DA, MD, PhD, “The importance of brain-derived neurotrophic factor in maintaining brain health during and after cancer treatments”, Hematolog Oncolog, DOI

· 10.26416/OnHe.42.1.2018.1554, 2018

1. Chan, S, MD, Liao, S, MD,… **Bota RG, MD**,… Wey, R, MD, “Implementation of a multidisciplinary palliative and supportive care education lecture series”, Journal of Clinical Oncology, 35(31\_suppl):144, 2017
2. Nguyen C, MD, Novac A, MD, Hazen J, MD, Tieu R, MS, **Bota RG**, MD, “Weigh effects of aripiprazole monotherapy compared with aripiprazole-antidepressant polypharmacy in an outpatient sample: A retrospective chart review of 1925 patients” Journal of Psychopharmacology, 12 1-7, 2017
3. Novac, A, MD, **Bota, RG, MD**, Blinder B, MD, “Identity Narative Density: Preliminary findings from scoring emotional valence of autobiographical events” Menninger Bulletin, 7 26:1-15, 2017
4. Torosyan, N, BS, Bota, RG, MD, “Social cognition in schizophrenia”, Mental Illness Journal, 9: 62, 2017
5. Wahid N, Kim JJ, MD, **Bota, RG, MD**, “Psychostimulant Use in Schizophrenia for the Treatment of Negative Symptoms and Weight Loss”, Primary Care Companion CNS Disorders, 19(0):17, 2017
6. Muniz Castro, H, BS, Alvarez, J, MD, **Bota, RG, MD,** Yonkers, M, MD, Tao, J, MD, “A Case of Attempted Bilateral Self-Enucleation in a Patient with Bipolar Disorder” Mental Illness Journal, 9(1), 2017
7. Bota RG MD, Groysman L, MD, Momii, A, “Catatonia as a Syndrome Characterized by GABAergic Interneuronal Dysfunction Mediated by NMDA Receptors” British Journal of Medicine and Medical Research, 19 (11) 1-6, 2017
8. Groysman L, MD, Nam K, MD, Vo N, Rocha R, MD, Cvetko J, MD, Kim J, MD, Al-obeidi E, MD, Cho C, MD and **Bota RG, MD**, “Catatonia eight years after the head injury” British Journal of Medicine and Medical Research, 19(4) 1-12, 2017
9. **Bota RG**, MD, Hazen J, MD, Tieu R, MS, Novac A, MD, “Mindfulness Based Cognitive Therapy for patients with depression decreases the need of outpatients visits” Primary Care Companion of CNS Disorders, 18(4), doi:10.4088, 2016
10. Vladu C, MD, Novac P, MD, Preda A, MD, **Bota RG, MD**, “No health without mental health”, Mental Illness Journal, 8(2), DOI: 10.4081, 2016
11. Rocha E, MD, Novac A, MD, Kristen D, MD, Shin J, MS, Totoiu D, **Bota R, MD**; “Psychosis, Catatonia and Post-psychosis PTSD”. British Journal of Medicine and Medical Research, 15(8) 1-5, 2016
12. Novac A, Pithia, N, MS, Nguyen B, MS, Krishnan S, MS, **Bota RG,** MD, “Writing on One’s Own Demise: Suicide notes in the Age of the Internet”. British Journal of Medicine and Medical Research, 15(7) 1-6, 2016
13. Nguyen C, MD, Bera K, **Bota R, MD**, Hsu R, “Biopsychosocial Approach to the Treatment of Obesity: A retrospective review”, HSOA Journal of Obesity& Weight Loss, 2(1) 1-4, 2016
14. Wong M, BA, Darvishzadeh A, BS, Maler N, BS, **Bota RG**, MD, “Dietary Supplement nomenclature”, PCC of CNS Disorders, 18(0), 1, 2016
15. Aragon, D, MD, Humphries P, MD, Heare M, MS, **Bota R, MD**; “Periodic catatonia after thyroid cancer” British Journal of Medicine and Medical Research, 14(5) 1-4, 2016
16. Wong M, BA, Darvishzadeh A, BS, Maler N, BS, **Bota RG**, MD, “Case report- Five supplements and multiple psychotic symptoms”, PCC of CNS Disorders, Jan, 2016
17. **Bota RG**, MD, Novac A, MD, Kheriaty A, MD, “Longitudinal Reflections of the Recent Political Shifts in the Prescription of Opiates” Mental Illness Journal, Sep 30; 7(2):6066, 2015
18. Preda A, MD, **Bota RG**, MD., “Schizophrenia” British Medical Journal Point of Care, (Peer-reviewed Book Chapter - for non US regions) 2015, first edition, yearly edited (electronic version in www.epocrates.com – for US)
19. **Bota RG**, MD., Preda A, MD, “Schizoaffective disorders” British Medical Journal Point of Care, (Peer-reviewed Book Chapter- for non US regions) 2012, first edition, yearly edited (electronic version in www.epocrates.com – for US)
20. Novac A, MD, Iosif AM, LVN, Groysman R, MD, **Bota RG**, MD, “Implications and longitudinal reflections of sensorineural hearing loss with hydrocodone/acetaminophen abuse”, PCC of CNS Disorders, Sep 10; 17(5)2015
21. Galant-Swafford J, BA, **Bota RG**, MD, “Musical hallucinations in Schizophrenia” Mental Illness Journal, 7(1):26-27, 2015
22. Cisneros V, MS, Goldberg I, MS, Schafenacker A, MS, **Bota RG**, MD, “Balancing Life in Medical School”, Mental Illness Journal, 7(1):5-6, 2015
23. Iyer V, MD, Choi B, MD, **Bota RG,** book review: “Unhinged: a memoir of enduring, surviving, and overcoming family mental illness”, Mental Illness Journal, 2:46, 2014
24. Florescu C, MA, MPH, Wood ML, BS, **Bota RG**, MD, book review: “From Science to Practice: A Global Health Approach to Child and Adolescent Mental Health”, Mental Illness Journal, 2:45, 2014
25. Novac A, MD, Bota DA, MD PhD, Witkowski J, MD, Jorge Lipiz, MD, **Bota RG**, MD, MSG, “Special Medical Conditions Associated with Catatonia in the Internal Medicine Setting- Hyponatremia inducing psychosis and subsequently catatonia” Permanente Journal, 18(3):78-81, 2014
26. Novac, A, MD, McEwen, S, PhD, **Bota RG**, MD, MSG: “Negative Rumor – Contagion of a Psychiatric Department”: Primary Care Companion for CNS disorders, 16(2):13br01614, 2014
27. Novac, A, MD, **Bota RG**, MD, MSG, “Transprocessing: a proposed neurobiological mechanism of psychotherapeutic processing”: Mental Illness Journal, 6:20-35, 2014
28. **Bota RG**, MD, “Schizophrenia traveler type”: Mental Illness, 5:e5:17, 2013
29. **Bota RG**, MD, “Cognition and closed systems”: Mental Illness, 5:e9:34, 2013
30. **Bota RG**, MD. MSG, Novac A, MD., “Transprocessing: Neurobiological Mechanisms of Change during Psychotherapy-A Proposal Based on a Case Report” Permanente Journal, 17(1):63-7, 2013
31. Nguyen C, MD., Rosen J, Pharm.D., **Bota RG**, MD., “Aripiprazole Partial Agonism at 5-HT2c: a Comparison of Weight Gain Associated with Adjunctive Aripiprazole to Antidepressants with High versus Low Serotonergic Activities.” Primary Care Companion for CNS disorders, 14(5): PCC.12m01386, 2012
32. **Bota RG**, MD., Preda A, MD, “Schizophrenia” British Medical Journal Point of Care, (Peer-reviewed Book Chapter - for non US regions) 2011, first edition, yearly edited (electronic version in www.epocrates.com – for US)
33. **Bota RG**, MD, MSG, Ligasan A., RN, Najdowski T.G., LCSW, Novac A. MD, “Valproic acid associated hypersensitivity syndrome; review of the literature and a case report” Permanente Journal, 15(2):54-58. 2011
34. **Bota RG**, MD, MSG, Preda A, MD, “The Self and Asperger syndrome” Southern Medical Journal, 104(4):251-2. 2011
35. **Bota RG**, MD, Munro JS, MD, Nguyen C, MD, Preda A, MD, “Course schizophrenia: What we learned from longitudinal studies” Schizophrenia Spectrum Disorders, Vol II, chapter 11, 1st Edition. Ritsner M. (ed), Elsevier. March 2011
36. Preda A, MD, **Bota RG**, MD, Harvey P, MD “Neurocognitive Deficits, Negative Symptoms, and Insight in Schizophrenia” Schizophrenia Spectrum Disorders, Vol II, chapter 2, 1st Edition. Ritsner M. (ed), Elsevier. March 2011
37. **Bota RG**, M.D., Ricci WF, M.D., Preda A. MD, ”Bypassing shame and conversion disorder” CNS Spectrums, 16(7):579-83. 2010
38. **Bota RG**, MD., Witkowski J, MD, “Quetiapine induced dystonia in a patient with history of severe head injury” Rehabilitation Process and Outcome, 3:1-4. 2010
39. **Bota RG**, M.D., Sagduyu K, M.D., Filin EE, M.D., Bota DA, M.D., Ph.D., Munro JS, M.D., “Toward a Better Identification and Treatment of Schizophrenia Prodrome” The Bulletin of the Menninger Clinic, 72(3):208-26. 2008
40. **Bota RG**, MD., “Prevention and Treatment of Suicidal Behaviour: From Science to Practice” PCC Journal of Clinical Psychiatry, 10(6):489-490. 2008
41. **Bota RG**, M.D., Dellembaugh T, M.D., Giorgadze A, M.D., Eaglin CK, MD, Davila MC, M.D., “Routine laboratory investigations in a publicly funded state hospital” Clinical Medicine- Psychiatry, 1:17-24. 2008
42. **Bota RG**, MD., Sagduyu K, MD., “Therapeutic dilemmas in treatment resistant bipolar patients” SMJ, 101(6):584. 2008
43. **Bota RG**, MD., “Schizophrenia” British Medical Journal Point of Care, (Peer-reviewed Book Chapter) 2007 (to 2011), first edition, yearly edited (electronic version in [www.epocrates.com](http://www.epocrates.com))
44. **Bota RG**, M.D., Ricci WF, M.D., “Empathy as a method toward identification the debut of the prodrome of schizophrenia” The Bulletin of the Menninger Clinic 71 (4):312-24. 2007
45. **Bota RG**, M.D., Munro JS, M.D., Sagduyu K, M.D., “Boarding Home placement in patients with schizophrenia: predictor of better prognosis” Southern Medical Journal 100 (2):145-8. 2007
46. **Bota RG**, M.D., Munro JS, M.D., Ricci WF, M.D., Bota DA, M.D., Ph.D. “Dynamics of insight in the prodrome of schizophrenia” CNS Spectrum 11(5):355-62. 2006
47. Davila MC, MD., **Bota RG**, MD., “Stressors and the fine line between normal and psychopathology” Southern Medical Journal. 99(3):201. 2006
48. **Bota RG**, M.D., “What We Know about Ourselves: Changing Attitude about Treating Patients with Substance Use Disorders” Southern Medical Journal, 99(1):11. 2006
49. **Bota RG**, M.D., Sagduyu K, M.D., Munro JS, M.D., “Factors associated with prodromal presentation that influences schizophrenia prognosis” CNS Spectrum. 10(12):937-42. 2005
50. **Bota RG**, M.D., Munro JS M.D., Sagduyu K, M.D., “Identification of the Schizophrenia Prodrome in a Hospital Based Patient Population” Missouri Medicine. 102(2) 154-8, 2005
51. Brody AL, M.D., Mandelkern MA, M.D., Ph.D., Jarvik ME, M.D., Lee GS, B.S., Smith EC, Huang JC, B.S., **Bota RG**, M.D., Bartzokis G, M.D. and London DE, Ph.D., “Differences between Smokers and Nonsmokers in Regional Gray Matter Volumes and Densities”, Biological Psychiatry, 55(1) 77-84, 2004
52. Brody AL, M.D., Mandelkern MA, M.D., Ph.D., London ED, Ph.D., Childress AR, Ph.D., **Bota RG**, M.D., Lee GS, B.S., Ho ML, B.S., Saxena S, M.D., Baxter LR, Jr., M.D., Madsen D, B.A., Jarvik ME, M.D., Ph.D., “Brain Metabolic Changes during Cigarette Craving”, Archives of General Psychiatry, 59 1162-1172, 2002
53. Brody AL, M.D., Barsom MW, M.D., **Bota RG**, M.D. and Saxena S, M.D. “Prefrontal- Subcortical and Limbic Circuitry Mediation of Major Depressive Disorder”, Seminars in Clinical Neuropsychiatry, 6(2)102-112, 2001
54. Saxena S, M.D., **Bota RG**, M.D. Brody AL, M.D., “Brain-Behavior Relationships in Obsessive-Compulsive Disorders”, Seminars in Clinical Neuropsychiatry, 6(2)82-101, 2001

ABSTRACTS

1. Bota, DA, MD, Di, K, PhD, Keator, DB, PhD, Bota, RG, MD, Levin, N, PhD, “[Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain](https://www.researchgate.net/publication/335052144_Abstract_4733_Human_functional_brain_imaging_data_support_preclinical_and_clinical_evidence_that_marizomib_crosses_the_blood-brain_barrier_BBB_to_inhibit_proteasome_activity_in_the_brain?_sg=qJMAJd0s6jBjWMrQCjBE1O3E6uULGbbCi5saoVRc17kbnF2_fwvVnWEfIcAfMCYckSpN62nR37YGnU6nYxEkkceYS8xFOlmyqm_uqrow.ryAH2s7g3b2Z-LkGJnwCuDq7ITfr26pou1szngniDC7Jp1g4Qnk12O-LSGxj6XFDWIRqgmSv9U_84iimnzEeTg), Conference Paper, July 2019, Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA
2. Bota, DA, MD, Di, K, PhD, Keator, DB, PhD, Bota, RG, MD, Levin, N, PhD, “[Abstract 4733: Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain](https://www.researchgate.net/publication/335052144_Abstract_4733_Human_functional_brain_imaging_data_support_preclinical_and_clinical_evidence_that_marizomib_crosses_the_blood-brain_barrier_BBB_to_inhibit_proteasome_activity_in_the_brain?_sg=qJMAJd0s6jBjWMrQCjBE1O3E6uULGbbCi5saoVRc17kbnF2_fwvVnWEfIcAfMCYckSpN62nR37YGnU6nYxEkkceYS8xFOlmyqm_uqrow.ryAH2s7g3b2Z-LkGJnwCuDq7ITfr26pou1szngniDC7Jp1g4Qnk12O-LSGxj6XFDWIRqgmSv9U_84iimnzEeTg), Conference Paper, July 2019, Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA
3. Sampathi, BR, Sofine, A, MD., Alvarez, J, MD, **Bota, RG, MD**, “Substance-Induced Capgras Syndrome via Folie a Deux”, 170th Annual Meeting of the American Psychiatric Association, San Francisco, May 2019
4. Reed, M, MD, Sampathi, B, Comeau, S, MD, Wojtanowicz, T, MD, Silva, A, Penev, S, MD, **Bota, RG,** **MD,** “Chlorpromazine and deep venous thrombosis”, 170th Annual Meeting of the American Psychiatric Association, San Francisco, May 2019
5. Bota, DA, MD, Di, K, Keator, DB, PhD, Small, SL, MD, **Bota, RG, MD**, Hoffman, M, Levin, N, MD, “Human Functional Brain Immaging Data Support Preclinical and Clinical Evidence That Marizomib Crosses the Blood-Brain-Barier to Inhibit Proteozome Activity in the Brain”, American Association for Cancer Research meeting, April, 2019
6. “Mirtazepine in patients with GBM on Temadar” 2019
7. Nguyen, BN, MD, Sofine, A, MD, **Bota, RG, MD**, “The effects of Transcranial Magnetic stimulation on Brain-Derived Neurotrophic factor”, Poster 28, Annual Meeting of the Clinical Transcranial Magnetic Stimulation Society, Vancouver, 2019
8. Sofine, A, MD, Nguyen, B, MD, Reed, M, MD, Matei, M, **Bota, RG, MD**, “Pilot study of Transcranial Magnetic Stimulation for the Treatment of Cognitive Impairment in Cancer Patients”, Annual Meeting of the Clinical Transcranial Magnetic Stimulation Society, Vancouver, 2019
9. Torisyan, N, Spencer, D, Penev, S, MD, **Bota, RG, MD**, “Psychogenic polydipsia in a woman with anorexia nervosa”, 169th Annual Meeting of the American Psychiatric Association, New York, May 2018
10. Shawna Chan, Solomon Liao, Leslie M. Randall, Aaron Kheriaty, Rakhi Dayal, Jeffrey V. Kuo, Joseph Nguyen, Charles Vega, **Robert Bota,** Cris Barrios, Mudit Dabral, Randy Wei, “Implementation of a multidisciplinary palliative and supportive care education lecture series” Palliative Care in Oncology Symposium from October 27-28, 2017 San Diego
11. Groysman, L, MD, Nam, K, MD, Vo, N, Rocha, E, MD, Cvetko, J, MD, Kim, J, MD, Al-obeidi, E, Cho, C, MD, **Bota, RG, MD** “Catatonia eight years after head injury”, 168th Annual Meeting of the American Psychiatric Association, San Diego, May 2017
12. Rocha, E, MD, Novac, A, MD, Kirsten, D, MD, Shin, J, MD, Totoiu, D, BS, **Bota, RG, MD,** “Psychosis, Catatonia and Post-psychosis PTSD”, 168th Annual Meeting of the American Psychiatric Association, San Diego, May 2017
13. Bui, A, MD, Novac, A MD, Kheriaty, A, MD, **Bota, RG, MD,** “Longitudinal reflections on the recent political shifts in the prescription of opiates”, 168th Annual Meeting of the American Psychiatric Association, San Diego, May 2017
14. *Marcus, M, MD, Lai, L, MD, Iyer, V., Miropolskiy, E, MD, Brockmann, B, MD, Serrato, J, MD, Yin, S, MD, Vu, T, MD, Howard, P, MD,* ***Bota, RG, MD.*** “Staggering Appointment Times and Impact on Quality of Encounters: A Pilot Study in a Psychiatric Residential Outpatient Clinic”, 168th Annual Meeting of the American Psychiatric Association, San Diego, May 2017
15. Aragon, D, MD, Heare, M, ***Bota, RG, MD.*** “Periodic Catatonia after Thyroid Cancer”, 168th Annual Meeting of the American Psychiatric Association, San Diego, May 2017
16. Bota, RG, MD, “Methodological considerations for use of r-TMS in patients with cancer diagnosis”, SfN Satellite Symposium-Spinal Cord Plasticity in Motor Control, San Diego, November, 2016
17. Suzuki A, MD, Marcus M, MD, Nguyen C, MD, Howard P, MD, Novac A, MD, Preda A, MD, **Bota RG, MD**, “Weigh effects of aripiprazole monotherapy compared with aripiprazole-antidepressant polypharmacy in an outpatient sample: A retrospective chart review of 1925 patients” 167th Annual Meeting of the American Psychiatric Association, May 2016
18. Lochhead J, MD, Nelson M, MD, Hazen J, MD, Tieu R, BS, Novac A, MD, **Bota RG**, MD, “Mindfulness-Based Cognitive Therapy for Major Depressive Disorder “, 167th Annual Meeting of the American Psychiatric Association, May 2016
19. Wong, M, BS, Darvishzadeh, Ayeh; Maler, N, BS, **Bota RG**, “Case report- Five Supplements and Multiple Psychotic Symptoms” 167th Annual Meeting of the American Psychiatric Association, May 2016
20. Vu, T, MD, Rocha, E, MD, Novac, A, MD, Groysman, R, MD, **Bota, RG, MD** “ Implications of sensorineural hearing loss with Hydrocodone/Acetaminophen abuse” US Psychiatric Congress, San Diego, Sept 11, 2015
21. **Bota RG**, MD, MSG, Nguyen, C, MD, “Weight Gain Associated With Aripiprazole Adjunctive to Antidepressants”, Poster presentation at 66th Institute on Psychiatric Services, San Francisco, November 1st, 2014
22. **Bota RG**, MD, Novac, A, MD, Witkowski, J, MD “Special Medical Conditions Associated with Catatonia in the Internal Medicine Setting- Hyponatremia inducing psychosis and subsequently catatonia” Psychologiche Medizin, 1 (EAPM), pg 18 2014
23. **Bota RG**, MD, “Negative Rumor  Contagion of a Psychiatric Department” Psychologiche Medizin, 1 (EAPM), pg 18 2014
24. **Bota RG**, MD, MSG, “Catatonia – changes in self relating vertical systems” Annual Meeting of the Europeean Association of Psychosomatic Medicine, Sibiu, Romania, June, 2014
25. **Bota RG**, MD, MSG, Witkowski, J, MD, Lipiz, J, MD, “Catatonia in medical setting-Hyponatremia inducing psychosis and subsequently catatonia”. Poster presentation at 26th US Psychiatric congress, Las Vegas, Nevada. October 2nd, 2013
26. Novac A, MD, **Bota RG**, MD, “Transprocessing: neurobiological mechanisms of change during psychotherapy”. Poster presentation at 165th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012
27. Totoiu D, **Bota RG**, MD, Opinion on Opinions, Poster presentation at 24th US Psychiatric Congress, Las Vegas, Nevada, November 2011
28. **Bota RG**, MD, “Schizophrenia traveler type” Schizophrenia Research, 2010
29. **Bota RG**, MD, “Schizophrenia traveler type” Schizophrenia Research, 2010
30. **Bota RG**, MD, “An alternate explanation to “cognitive dysmetria” in schizophrenia” Schizophrenia Bulletin 2009 February (Control ID 543785)
31. **Bota RG**, MD, Ricci WF, MD, Preda A, MD , “Bypassing shame and conversion disorder”, 17th European Congress of Psychiatry. Lisbon, January 24-28, 2009
32. **Bota RG**, MD, Bota DA, MD, PhD, “Theoretical model of insight”, European Psychiatry. 22(1) S105 March 2007
33. **Bota RG**, MD, Ricci WF, MD, Bota DA, MD, PhD, “Empathy as method toward the identification of the debut of schizophrenia prodrome”, European Psychiatry. 22(1) S105-6 March 2007
34. **Bota RG**, MD, Munro JS, MD, Kim P, DO, Le V MD, Sagduyu K, MD. “Prognosis implications of the prodromal course of schizophrenia” Poster Presentation at Southern Medical Association, 100th Annual Scientific Assembly, November, 2006, Charlote NC
35. **Bota RG**, MD, Bota DA, MD, PhD, “Tripartite model of the mind; an alternate explanation to cognitive dysmetria in schizophrenia” PSY-3, Poster Presentation at Southern Medical Association, 100th Annual Scientific Assembly, November, 2006, Charlote NC
36. **Bota RG**, MD, Morgan G, MD, Dellembaugh T, MD, Giorgadze A, MD, Le V, MD, Davila MC, MD, “Usefulness of routine laboratory investigations in a psychiatric hospital” PSY-2, Poster Presentation at Southern Medical Association, 100th Annual Scientific Assembly, November, 2006
37. **Bota RG**, M.D. “Tripartite model of the mind; an alternate explanation to “cognitive dysmetria” in schizophrenia” Poster presentation at 159th Annual Meeting of the American Psychiatric Association May 2006, Toronto, Canada
38. **Bota RG**, M.D., Munro JS M.D., Sagduyu K, M.D., “Protective effect of pharmacological treatment in early schizophrenia” (abstract has been chosen as 1 of the Best 25 of >400 participating abstracts) Southern Medical Journal. 98(10) S32, October 2005.
39. **Bota RG**, M.D., Munro JS M.D., Sagduyu K, M.D., “Boarding home placement in patients with schizophrenia: predictor of better prognosis” (abstract has been chosen as 1 of the Best 25 of >400 participating abstracts) Southern Medical Journal. 98(10) S31-S32, October 2005.
40. **Bota RG**, M.D., Munro JS M.D., Sagduyu K, M.D., “Insight preservation in early schizophrenia predicts better prognosis” Southern Medical Journal. 98(10) S33, October 2005.
41. **Bota RG**, M.D., Munro JS M.D., Sagduyu K, M.D., “Identification of the Prodrome of Schizophrenia” Southern Medical Journal. 97(10) S65, 2004
42. **Bota RG**, M.D., Munro JS M.D., Davila MC, M.D., Sagduyu K, M.D., "Prognostic Value Of Symptoms Identification In The Prodromal Phase Of Schizophrenia" in: Clinical Vignette category of the Annual Meeting of the American Medical Association-RFS, November 4, 2005, Dallas, TX
43. **Bota RG**, M.D., Munro JS M.D., Davila MC, M.D., Sagduyu K, M.D., "Implications of Boarding home placement in patients with schizophrenia" in: Clinical Medicine category of the Annual Meeting of the American Medical Association-RFS, November 4, 2005, Dallas, TX
44. **Bota RG**, M.D., Munro JS M.D., Sagduyu K, M.D., “Boarding Home placement in patients with schizophrenia: predictor of better prognosis” Presentation Poster at 57th Institute on Psychiatric Services-APA, October, 2005
45. **Bota RG**, M.D., Munro JS M.D., Sagduyu K, M.D., “Antipsychotic treatment in the prodromal phase of schizophrenia: predictor of better prognosis” Presentation Poster at 57th Institute on Psychiatric Services-APA, October, 2005
46. **Bota RG**, M.D., Munro JS M.D., Sagduyu K, M.D., “Dynamics of insight in the prodrome of schizophrenia” In: Young Investigators’ Presentation Poster at 57th Institute on Psychiatric Services-APA, October, 2005
47. **Bota RG**, M.D., Munro JS M.D., Sagduyu K, M.D., “Early symptoms presage schizophrenia” Presentation poster at annual meeting of KCALSI 2005
48. **Bota RG**, M.D., Munro JS M.D., Sagduyu K, M.D., “Antipsychotic treatment in the prodromal phase of schizophrenia: predictor of better prognosis” In: Young Investigators’ Poster Session of the 158th Annual Meeting of the American Psychiatric Association; May 23, 2005; Atlanta, GA. Abstract NR86
49. **Bota RG**, M.D., Munro JS M.D., Sagduyu K, M.D., “Dynamics of insight in the prodrome of schizophrenia” In: Young Investigators’ Poster Session of the 158th Annual Meeting of the American Psychiatric Association; May 23, 2005; Atlanta, GA. Abstract NR85
50. **Bota RG**, M.D., Munro JS M.D., Filin EE, M.D., Sagduyu K, M.D., “Identification of the Prodrome of Schizophrenia” Presentation Poster at 56th Institute on Psychiatric Services-APA, October 8, 2004; Atlanta,GA. Abstract NR1657
51. **Bota RG**, M.D., Munro JS M.D., Filin EE, M.D., Sagduyu K, M.D., "Toward early detection of schizophrenia in the Emergency Room setting" in: Original Research Poster Session of the Annual Meeting of the American Medical Association-RFS, December 3, 2004; Atlanta, GA. Abstract Pg.42
52. Brody AL, M.D, Mandelkern MA, M.D, Ph.D, London ED, Ph.D., Childress AR, Ph.D, **Bota RG**, M.D, Lee GS, B.S, Ho ML, S, Saxena S, M.D, Baxter LR, Jr., M.D, Madsen D, B.A, Jarvik ME, M.D, Ph.D, “Cue-Induced Craving for Cigaretes: PET Studies of Smokers and Nonsmokers” Poster presented at 39th Annual Meeting at American College of Neurophychopharmacology, San Juan, Puerto Rico, December 11, 2000

ORAL PRESENTATIONS

1. **Bota, RG, MD** “Stress management/ Physician Burnout” West Anaheim Medical Center. 02/12/ 2021
2. **Bota, RG, MD** “Dealing with stress in covid time” FVRH, 08/31/2020
3. **Bota, RG, MD** "What comes next for Patients with Treatment-resistant Mental Illnesses". Rainier Springs, 08/06/2020
4. **Bota, RG, MD** “Treatment resistant depression- The role of TMS” A Better life recovery, May 2, 2020
5. **Bota, RG, MD** “Stress management/ Physician burnout”, West Anaheim Medical Center, Anaheim, April 17, 2020
6. **Bota, RG, MD** “Anxiety from boredom to burnout” ”. Nursing forum, Feb 21, 2020
7. **Bota, RG, MD** “Management of psychiatric patients in ED”. Nursing forum, Feb 14, 2020
8. **Bota, RG, MD,** “Management of Psychiatric Patients in Acute Settings” San Antonio Hospital, Upland, Jan 9 2020
9. **Bota, RG, MD** “TMS in clinical practice” Mission for Michael, San Juan Capistrano, Nov 20, 2019
10. **Bota, RG, MD,** “Depression in older adults”, Newport Library, Nov 18, 2019
11. **Bota, RG, MD,** “Burnout- Healing the healer” Stop Cancer, Bucharest, May 10, 2019
12. **Bota, RG, MD,** “r-TMS for depression”, Grand Rounds, UC Irvine, March 13th, 2019
13. **Bota, RG, MD,** “Anxiety, from boredom to burnout”, Stigma Free UC Awareness Initiative, February 19, 2019
14. **Bota, RG, MD,** “Psycho oncology- a value proposition in multidisciplinary oncology treatment” Los Alamitos Hospital, January 28, 2019
15. **Bota, RG, MD,** “Identity Narrative as an Unconscious Neurobiologicat Scaffold for Human Autobiography” 16th International Conference on Social Sciences, November, 2018
16. **Bota, RG, MD,** “Psycho oncology- a value proposition in multidisciplinary oncology treatment” Annual congress of Romanian cancer Society, Poiana Brasov, September, 2018
17. **Bota, RG, MD,** “The effect of cancer and cancer treatment on the brain: the interface between cancer care and psychiatry” Stop Cancer, Bucharest, May, 2018
18. **Bota, RG, MD,** “The effect of cancer and cancer treatment on the brain: the interface between cancer care and psychiatry” Annual congress of Romanian cancer Society, September 28, 2017
19. **Bota, RG, MD,** “Treatment of psychiatric co-morbidities in patients **Bota, RG, MD,** “*Biases and heuristics in decision making”*  May 1st Tobis Ethics Journal Club, 2017
20. **Bota, RG, MD,** “Treatment of Psychiatric Comorbidities in Patients with Cancer” Good Samaritan Hospital, Sep. 13 2017
21. **Bota, RG, MD,** “Depression and stress”, Senior Center, Yorba Linda, March, 2017
22. **Bota, RG, MD,** “Treatment of psychiatric co-morbidities in patients with cancer” at Romanian Cancer Society and Geriatric European Conference, October, 2016
23. **Bota RG**, MD, “Psychiatric Complications of Medical Illness” CME presentation Good Samaritan Hospital Grand Rounds, 1/28/2015
24. **Bota RG**, MD, “Psychiatric Complications of Medical Illness” CME presentation Chino Valley Medical Center, 1/29/2015
25. **Bota RG**, MD, “Psychiatric Complications of Medical Illness” CME presentation San Dimas Community Hospital, 1/8/2015
26. **Bota RG**, MD, “Negative Rumor  Contagion of a Psychiatric Department” Annual Meeting of the Europeean Association of Psychosomatic Medicine, Sibiu, Romania, June, 2014
27. Novac A, MD, **Bota RG**, MD, “Neurobiological basis of processing” World Congress of Psychiatry, Bucharest, Romania, April, 2013
28. **Bota RG**, MD, “Usefulness of routine laboratory investigations in a psychiatric hospital” Lecture at Southern Medical Association, 100th Annual Scientific Assembly, November 13, 2006
29. **Bota RG**, M.D., “Toward early recognition of the prodrome of schizophrenia” Oral presentation in grand round series (CME) at East Carolina University on August 24, 2006
30. **Bota RG**, MD., “Treatment of behavioral disturbances in dementia” CME Presentation, Macon GA, August 2006
31. **Bota RG**, M.D., “Psychotic illnesses, concept, identification and treatment” Oral presentation in grand round series (CME) at Sumter Regional Hospital, GA on April 27, 2006
32. **Bota RG**, M.D., “Protective effect of pharmacological treatment in early schizophrenia” Lecture, Southern Medical Association, 99th Annual Scientific Assembly, November 11, 2005
33. **Bota RG**, M.D., “Boarding home placement in patients with schizophrenia: predictor of better prognosis” Lecture, Southern Medical Association, 99th Annual Scientific Assembly, November 11, 2005
34. **Bota RG**, M.D., “Insight preservation in early schizophrenia predicts better prognosis” Lecture, Southern Medical Association, 99th Annual Scientific Assembly, November 11, 2005
35. **Bota RG**, M.D., " Protective effect of pharmacological treatment in early schizophrenia" Research day presentation at St. Lukes Hospital on 5/6/2005
36. **Bota RG**, M.D. “The Prodrome of Schizophrenia-course and interventions” Oral presentation in grand round series (CME) at University of Missouri at Kansas City, Psychiatry Department, 4/20/2005
37. **Bota RG**, M.D. “Toward early recognition of the prodrome of schizophrenia” Oral presentation in seminar series at Washington University School of Medicine, Department of Psychiatry, 1/20/2005
38. **Bota RG**, M.D., Filin EE, M.D., Munro JS M.D., "Early detection of schizophrenia in the Emergency Room setting" Research day presentation at Harvard University on 10/8/2004

LECTURES/COURSES TAUGHT

*University of California Irvine*

2018- now Interventional psychiatry course for 2nd year

2017- now Mood disorders for medical students, every 6 weeks

2017 Anxiety disorders for medical students, every 6 weeks

2015-now Neuromodulation- PGY3 (DBS, TMS)

2016- 2018 Catatonia- PGY1

2016- now Psycho oncology- Palliative Care

2016 Psychiatric complications of neurological disorders- Neurology residents

2016- now Management of anxiety and depression- Primary Palliative Care Lecture Series

2016- 2017 Substance Abuse class for internal medicine residents

2015- now Substance Abuse class for 3rd year medical students

2014- 2016 Psychopharmacology for PGY 1&2

2015- now Psychosocial aspects of pain for Chronic pain fellowship

2014- now How to review scientific articles for PGY 1&2 and medical students yr 3-4

2014- now Writing editorials, reviews and case reports for PGY 1&2 and medical students yr 3-4

*University of Missouri, Kansas City Medical Center, Department of Psychiatry:*

2002-2005 Introduction to psychiatry course for psychiatry residents

2003-2005 Schizophrenia course for psychiatry residents

2004-2005 Depression course for psychiatry residents

2004-2005 Substance use course for medical students

*University of Southern California*

1999-2000 Advanced biochemistry (Teaching Assistant)